Health Care

Siemens Healthineers grapples with margin pressure, regulatory headwinds, and a looming €13.9 b debt load—yet its AI‑driven imaging and radiopharma strategy may unlock new precision‑medicine growth, offering a path to sustainable shareholder value.

AbbVie’s Q1 2026 earnings show $4.72 bn in revenue, a 3.8 % rise driven by Humira and oncology products, while $7.9 bn R&D fuels a robust pipeline of next‑generation biologics.

Healthcare delivery amid shifting economics: How value‑based contracts, AI, tele‑health and workforce strategies can boost margins, quality, and patient access.

Fresenius SE’s shares climb 0.4% amid a flat DAX, outpacing peers and delivering steady returns driven by robust dialysis innovation and a 45% dividend payout.

Read how Bayer’s shares slipped ahead of a U.S. glyphosate trial, with investors weighing potential settlements and the broader market’s geopolitical backdrop.

Merck KGaA’s latest earnings reveal steady €20 bn revenues and €4 bn net income, while a strategic partnership with Remepy blends biologics with AI‑driven digital therapeutics, positioning the company to navigate patent cliffs, secure payer value, a…

UnitedHealth’s Q1 earnings beat expectations, lifting its stock and boosting the broader healthcare sector. The company’s higher margins, strategic acquisitions, and digital‑health investments signal strong growth and resilience amid economic headwi…

Pfizer’s Vyndamax patent settlement extends exclusivity to 2031, boosting revenue and positioning the drug amid rising competition and value‑based pricing shifts.

Johnson & Johnson cuts clinical‑documentation time from 700 hrs to 15 mins with AI, slashing costs and speeding drug launches – investors see a modest, optimistic uptick.

Fresenius Medical Care AG’s cash‑flow surge drives Citi’s €40 target, outpacing peers and showing disciplined growth amid Germany’s volatile market.